The CDC Group invests $21mn to the Asian Institute of Medical Sciences (AIMS)
With ambitions to develop businesses across Africa and Asia, boost the number of employment roles and improve local economies, The CDC Group has recently placed significant investment in healthcare provider Asian Institute of Medical Sciences (AIMS)
Established in 1948, the CDC remains the UK’s oldest Development Finance Institution (DFI) and is solely owned by the UK government. Investing up to US$21mn will see the Group work to improve present healthcare services across India, as well as support the development of a five-year hospital expansion into tier 2 and 3 cities in Jharkhand, Bihar and Uttar Pradesh.
The project will see the creation of up to 2,000 new healthcare roles, provide room for up to a thousand new hospital beds at existing facilities and guarantee essential medical training for staff members.
- Shanghai Henlius Biotech Inc is reportedly planning its IPO offering
- The UAE and the US extend their partnership with new stroke initiative
- Al Mazaya Holding completes its new medical centre in Kuwait
''We're pleased to be able to support a healthcare company that will reach patients that currently have to travel many hours to large cities like Delhi and Calcutta to receive the treatment they need,” commented Srini Nagarajan, managing director and head of South Asia for CDC.
“Our investment in Asian will increase access to high quality care in poorer and under-served cities in Northern and Central India. It will also create many jobs and training opportunities in these cities.”
With three tertiary care hospitals, two secondary hospitals and three health clinics, AIMS has received both NABH and NABL accreditation, with the aim to continually meet the needs of its patients through the use of digital tools and innovative solutions. This is only complemented further through its specialities in cardiology, oncology, orthopaedics and more.
''At Asian, we firmly believe that quality healthcare is a basic need and it needs to be delivered closer to where there is need and not only in big metropolitan centres. We already have our footprint in tier 2 and tier 3 towns. Our association with CDC is going to support us in expanding our services further in states like UP, Bihar and Jharkhand,'' added founder of AIMS N K Pandey.
Data de-identification - why it matters in healthcare
Large amounts of healthcare data is generated yet goes unused due to privacy concerns. To address this, data privacy firm TripleBlind has created Blind De-identification, a new approach that allows healthcare organisations to use patient data while eliminating the possibility of the user learning anything about the patient’s identity.
We asked Riddhiman Das, co-founder and CEO to tell us more about data de-identification.
Why is data de-identification important in healthcare?
Blind De-identification allows every attribute of any given dataset to be used, even at an individual level, while being compliant to privacy laws, rules, and regulations by default.
Governments around the world are adopting global data privacy and residency laws like GDPR, which prohibit citizens’ personally identifiable information data from leaving the borders of the country. While great for data protection, data residency laws result in global silos of inaccessible data. TripleBlind allows computations to be done on enterprise-wise global data, while enforcing data residency regulations.
In the US, HIPAA compliance has relied on what is called the Safe Harbor method, which requires removing 18 types of personal patient identifiers like names, email addresses, and medical record numbers. The Safe Harbor method can be too restrictive with the data or can leave too many indirect identifiers, which puts the patient data security at risk. Getting de-identification wrong could make an organisation liable for a costly mistake.
What does TripleBlind's solution do?
With TripleBlind, data is legally de-identified in real time with practically 0% probability of re-identification. Our solution allows analytics on data containing personally identifiable information and protected health information with zero possibility of re-identifying an individual from the dataset. This allows healthcare organisations to access more meaningful data, creating more accurate and less biased results.
For example, a healthcare drug researcher in a rural, predominantly white area, would only have patient data that would reflect their local population. With TripleBlind’s de-identification, they could more easily leverage third-party data from another healthcare facility in a more diverse region, creating a more complete data set that more accurately reflects the larger population. This has the possibility to create more accurate diagnoses and better drug results for more diverse populations.
How can healthcare organisations use this in practice?
TripleBlind is blind to all data and algorithms. That means we never take possession of customer data. We only route traffic between entities, enforce permissions, and provide audit trails. The enterprise’s data remains under their control. TripleBlind does not host, copy or control their data, algorithms or other information assets, ever.
We facilitate a connection to an encrypted version of their information assets. Our technology allows the algorithms and data to interact in an encrypted space that only exists for the duration of the operation. Organisations use their existing infrastructure, so it’s not hardware dependent.